Catalyst Crew Technologies Corp. (OTC: CCTC) has announced the development of NeuroAI, an artificial intelligence-enabled module designed to support neurological analysis and predictive risk modeling. The new platform is intended to assist healthcare providers in analyzing neurological data and identifying potential clinical risks through AI-driven analytics, according to a press release from the company.
NeuroAI’s proposed capabilities include early detection of neurological abnormalities, predictive modeling of cerebrovascular events, and AI-assisted analysis of brain imaging and cognitive data. The platform is being developed to integrate multiple data inputs, such as magnetic resonance imaging (MRI), electroencephalograms (EEG), cognitive assessments, and patient-specific data, to generate structured outputs aimed at supporting clinical review and care coordination.
This module is part of the company’s broader artificial intelligence healthcare platform and is expected to function as a specialized component within Catalyst Crew’s digital health ecosystem. Management believes that modular AI systems like NeuroAI may support scalable deployment across telehealth services, remote monitoring, and technology-enabled healthcare delivery environments.
Catalyst Crew Technologies intends to integrate NeuroAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, NeuroAI is expected to provide data-driven insights and clinical decision-support capabilities across neurological care pathways.
The company plans to prioritize market development in Latin America, where it believes AI-enabled healthcare technologies can help expand access to neurological evaluation tools, support early identification of conditions, and improve healthcare system efficiency. Dr. Kevin Rodan Levy, Chief Executive Officer, stated: "Advancements in artificial intelligence present new opportunities to assist in the early identification and monitoring of neurological conditions. NeuroAI is part of our broader strategy to develop integrated, scalable healthcare technologies that can support medical professionals and improve patient care."
Catalyst Crew Technologies is actively executing its strategic transition into AI-enabled healthcare and pursuing opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms. The company is focused on building an integrated healthcare technology platform to address the growing demand for modernized healthcare delivery systems in emerging markets.
For more information, visit https://catalystcrewai.com or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
